A large proportion of US adults prescribed Schedule II stimulants are simultaneously receiving other CNS agents, including benzodiazepines, opioids, and antidepressants.
This Viewpoint discusses the settlement agreements reached against several major pharmaceutical distributors resulting from the US opioid epidemic and how those
FDA Reviewers: Why We Are Against Approval of Aducanumab medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
It is only natural that individuals taking immunosuppressive medications would fear COVID-19.
However, recent findings add to a growing body of data indicating that immunosuppression may not elevate risk for worse outcomes for COVID-19 hospitalization. “This is a small amount of good news at a time in this pandemic when we need it,”
G. Caleb Alexander, MD, MS
, told H
ealio Rheumatology. “Doctors and patients may have been deciding to discontinue these medications to this point. We are starting to see that there is no need for this.”